{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wessels HJCT"],"funding":["Dutch Research Council (NWO)"],"pagination":["179-192"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11258658"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["61"],"pubmed_abstract":["<h4>Introduction</h4>The human plasma glycoproteome holds enormous potential to identify personalized biomarkers for diagnostics. Glycoproteomics has matured into a technology for plasma N-glycoproteome analysis but further evolution towards clinical applications depends on the clinical validity and understanding of protein- and site-specific glycosylation changes in disease.<h4>Objectives</h4>Here, we exploited the uniqueness of a patient cohort of genetic defects in well-defined glycosylation pathways to assess the clinical applicability of plasma N-glycoproteomics.<h4>Methods</h4>Comparative glycoproteomics was performed of blood plasma from 40 controls and 74 patients with 13 different genetic diseases that impact the protein N-glycosylation pathway. Baseline glycosylation in healthy i"],"journal":["Journal of advanced research"],"pubmed_title":["Plasma glycoproteomics delivers high-specificity disease biomarkers by detecting site-specific glycosylation abnormalities."],"pmcid":["PMC11258658"],"funding_grant_id":["184.034.019"],"pubmed_authors":["Kulkarni P","Pengelley S","van Dael M","Kragt E","Zijlstra F","Willems E","Gloerich J","Suppers A","Marx K","Schmit PO","Lefeber DJ","Wessels HJCT","van Gool AJ"],"additional_accession":[]},"is_claimable":false,"name":"Plasma glycoproteomics delivers high-specificity disease biomarkers by detecting site-specific glycosylation abnormalities.","description":"<h4>Introduction</h4>The human plasma glycoproteome holds enormous potential to identify personalized biomarkers for diagnostics. Glycoproteomics has matured into a technology for plasma N-glycoproteome analysis but further evolution towards clinical applications depends on the clinical validity and understanding of protein- and site-specific glycosylation changes in disease.<h4>Objectives</h4>Here, we exploited the uniqueness of a patient cohort of genetic defects in well-defined glycosylation pathways to assess the clinical applicability of plasma N-glycoproteomics.<h4>Methods</h4>Comparative glycoproteomics was performed of blood plasma from 40 controls and 74 patients with 13 different genetic diseases that impact the protein N-glycosylation pathway. Baseline glycosylation in healthy i","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-01T06:42:55.371Z","creation":"2025-05-18T13:26:26.588Z"},"accession":"S-EPMC11258658","cross_references":{"pubmed":["37683725"],"doi":["10.1016/j.jare.2023.09.002"]}}